TPWA
ATYR

Twin Peaks Wealth Advisors’s aTyr Pharma ATYR Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,815
Closed -$9.49K – 2230
2025
Q2 		$9.49K Buy
+1,815
New +$7.14K ﹤0.01% 960

Other funds holding ATYR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Twin Peaks Wealth Advisors's ATYR Position: Q3 2025 in Review

Twin Peaks Wealth Advisors sold out of aTyr Pharma (ATYR) in Q3 2025, closing a stake of 1,815 shares — an estimated $9.49K sold.

Twin Peaks Wealth Advisors first reported a position in ATYR in Q2 2025 and held it in 1 quarter. The position peaked at $9.49K in Q2 2025. 103 funds tracked by Wall St. Rank hold ATYR as of Q3 2025.

  • Twin Peaks Wealth Advisors reported no remaining aTyr Pharma position as of Q3 2025 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 1,815 aTyr Pharma shares in Q3 2025, an estimated $9.49K.
  • Twin Peaks Wealth Advisors first reported a position in aTyr Pharma in Q2 2025 and held it in 1 quarter.
  • Twin Peaks Wealth Advisors's aTyr Pharma position peaked at $9.49K in Q2 2025.
  • 103 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2025.

Based on Twin Peaks Wealth Advisors's 13F filing for Q3 2025, filed 30 Oct 2025.